Systemic lupus erythematosus Trials in New York, United States
Conditions / Systemic lupus erythematosus / New York, United States
Clinical trials for Systemic lupus erythematosus investigate a range of treatment strategies and patient populations.
80 total trials for this combination
Showing top 10 of 80 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00410384 | A Study of Belimumab in Subjects With Systemic Lupus Erythematosus | COMPLETED | PHASE3 |
| NCT01484496 | A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) | COMPLETED | PHASE3 |
| NCT05869955 | A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) | RECRUITING | PHASE1 |
| NCT01408576 | Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus | COMPLETED | PHASE3 |
| NCT05843643 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | — |
| NCT06617325 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | RECRUITING | — |
| NCT03843125 | A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) | TERMINATED | PHASE3 |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | RECRUITING | — |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | RECRUITING | — |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | RECRUITING | — |